10-Jun-2026
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
TipRanks (Thu, 11-Jun 7:33 AM ET)
Globe Newswire (Thu, 11-Jun 7:00 AM ET)
C4 Therapeutics to Participate in Upcoming Conferences
Globe Newswire (Wed, 20-May 7:00 AM ET)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 18-May 4:01 PM ET)
C4 Therapeutics Extends Cash Runway and Advances Cemsidomide as Phase 2 Clinical Trials Progress
Market Chameleon (Wed, 13-May 6:32 AM ET)
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Tue, 12-May 7:00 AM ET)
Globe Newswire (Thu, 9-Apr 6:59 AM ET)
Globe Newswire (Wed, 25-Mar 7:00 AM ET)
C4 Therapeutics Readies for Two Major March Conferences: What Investors Should Watch
Market Chameleon (Tue, 24-Feb 5:32 AM ET)
Market Chameleon (Thu, 16-Oct 7:22 AM ET)
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
C4 Therapeutics trades on the NASDAQ stock market under the symbol CCCC.
As of June 10, 2026, CCCC stock price climbed to $3.87 with 2,086,873 million shares trading.
CCCC has a beta of 2.51, meaning it tends to be more sensitive to market movements. CCCC has a correlation of 0.11 to the broad based SPY ETF.
CCCC has a market cap of $427.90 million. This is considered a Small Cap stock.
Last quarter C4 Therapeutics reported $6 million in Revenue and -$.20 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.
In the last 3 years, CCCC traded as high as $11.88 and as low as $1.06.
The top ETF exchange traded funds that CCCC belongs to (by Net Assets): VTI, FESM, VXF, IBB, SCHA.
CCCC has outperformed the market in the last year with a price return of +146.5% while the SPY ETF gained +21.5%. CCCC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +24.0% and +3.5%, respectively, while the SPY returned +7.4% and -3.3%, respectively.
CCCC support price is $3.33 and resistance is $3.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CCCC shares will trade within this expected range on the day.